Treatment News : Favoring ARVs for HIV Subgroups May Better Thwart Epidemic

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2014

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 16, 2014

Favoring ARVs for HIV Subgroups May Better Thwart Epidemic

In the absence of universal antiretroviral (ARV) treatment, prioritizing HIV meds for specific high-risk subgroups may have a greater effect on curbing the epidemic, aidsmap reports. Grounded in the fact that successful HIV treatment greatly lowers, and perhaps eliminates, the likelihood of transmitting the virus, this theory is derived from a new approach to identifying central drivers of the epidemic. Brian Williams, of the South African Centre for Epidemiological Modeling and Analysis, presented his epidemiological model at the 2014 Treatment as Prevention Workshop in Vancouver.

Williams and his team developed this model from HIV surveillance data about Can Tho, a south Vietnam province. His theory is based on a novel approach to analyzing the risk of HIV transmission: determining the number of people to whom an HIV-positive person may transmit the virus during his or her lifespan or time living with the virus. If this reproduction number, or R0, is smaller than 1 the epidemic will contract; if it is greater than 1, the epidemic will expand.

The researchers analyzed data on various subgroups of the 5,000 people living with HIV in Can Tho and determined that their average R0 was a relatively staggering 22. (Sub-Saharan Africa’s average R0 is only about 5.) Consequently, at least 96 percent of the population would have to be on ARVs with a fully suppressed viral load in order for the treatment as prevention (TasP) tactic to end the local HIV epidemic.

The respective R0’s for subgroups are as follows: female sex workers who inject drugs, 99; female sex workers, 77; men who have sex with men (MSM) who inject drugs, 27.4; non-MSM injection drug users, 21.5; non-injection drug using MSM, 6.1; clients of female sex workers, 0.061; low-risk women, negligible.

While prioritizing treatment specifically for the group with the highest R0, female sex workers who inject drugs, might seem logical, in fact it is the injection drug users in general who are at the core of the transmission network. These individuals are the most likely to serve as conduits of the virus, both acquiring the virus from and transmitting to others with high R0 scores.

Williams concluded that TasP would have the greatest effect on the future scope of the HIV epidemic in this area if ARVs were prioritized for those who inject drugs as well as for female sex workers.

To read the aidsmap story, click here.

Search: RO score, aidsmap, HIV, treatment as prevention, TasP, Treatment as Prevention Workshop, prioritizing treatment, Can Tho, Vietnam.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dlw8585
    Fort Lauderdale
    Florida


    juliar33
    brooklyn
    New York


    ernienyc
    Bronx
    New York


    josebos
    Boston strong
    Massachusetts
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.